POS0756 EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC NON-INFECTIOUS NON-ANTERIOR UVEITIS: REAL-LIFE EXPERIENCE FROM AIDA INTERNATIONAL REGISTRY

Background Evidence about the effectiveness of tumor necrosis factor inhibitor adalimumab (ADA) in pediatric patients with non-infectious intermediate uveitis/pars planitis, posterior uveitis and panuveitis is still limited. Objectives Aim this study to investigate therapeutic role ADA a cohort non-anterior uveitis. Methods This an international multicenter based on real-life data from treated due Data were drawn retrospective branch AutoInflammatory Disease Alliance (AIDA) registry dedicated Figure 1 provides flow diagram describing selection enrolled October 1st, 2022. Results 21 (36 affected eyes) enrolled. Eleven (19 did not experience further ocular inflammation after introduction; 10 cases (17 showed partial response reduced frequency relapses (3 cases), severity cases) or (4 cases). The number flares dropped 3.91 1.1 events/patient/year introduction ( p =0.0009). Macular edema retinal vasculitis respectively observed 18 eyes 20 at start 4 2 last assessment. mean daily glucocorticoids dosage significantly decreased assessment =0.005). As Table 1, planitis =0.01) =0.03) more frequent among full ADA; was continuing uveitic =0.001). Regarding safety profile, case generalized adenopathy observed. Conclusion had all significant glucocorticoid sparing effect. Panuveitis seems be flares. 1. Study illustrating process leading patients. Abbreviations: ADA, adalimumab; AIDA, Alliance; NIU, Baseline features showing control (group 1) those experiencing despite improvement and/or IBD: inflammatory bowel disease; IQR, interquartile range JIA: juvenile idiopathic arthritis; VKH: Vogt-Koyanagi-Harada syndrome; CS: corticosteroids. Group – no value N° patients/eyes 11/19 10/17 Male/Female, 6/5 7/3 0.96 Mean age onset, years (mean ± SD) 10.8 3.8 7.7 3.6 0.08 Unilateral/bilateral involvement onset 3/8 2/5 0.83 duration introduction, months median (IQR) 11 (24) 12 (17) 0.97 follow-up, (15) 27 (28.5) Anatomical classification, (%) Pars (52.6) Posterior, 5 (26.3) Panuveitis, (11.8) 0 (0) 14 (82.4) 0.01 0.03 0.001 Uveitis presentation, Sudden, 9 (47.4) Insidious, Unknown, (5.3) (70.6) (29.4) 0.16 0.28 course, Acute, (10.5) Recurrent, 3 (15.8) Chronic, (63.2) (58.8) 7 (41.2) 0.18 0.008 0.19 Concomitant systemic diseases, Idiopathic, (63.6) Behçet’s disease, (18.2) IBD, (9.1) Scleroderma, 6 (60) JIA, (20) VKH syndrome, (10) 0.92 molecule used, Originator, (45.5) ABP501, (27.3) SB5, GP2017, (60%) 0.52 CS treatment 8 (73.7) 0.55 cDMARDs (90) 0.17 REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.